Targeting Glucocorticoid Metabolism in Prostate Cancer
Open Access
- 28 June 2021
- journal article
- research article
- Published by The Endocrine Society in Endocrinology
- Vol. 162 (9)
Abstract
In the treatment of metastatic prostate cancer, resistance to hormonal therapy is a major obstacle. With antiandrogen therapies that suppress androgen signaling through the androgen receptor (AR), the primary driver of prostate cancer, some malignancies are able take advantage of the closely related glucocorticoid receptor (GR). Escape from AR dependency often involves a simple functional switch from 1 steroid receptor to another. Recent research efforts have outlined the mechanism enabling this switch, which involves alterations in glucocorticoid metabolism that occur with antiandrogen therapy to increase tumor tissue glucocorticoids and enable GR signaling. Targeting this mechanism pharmacologically by blocking hexose-6-phosphate dehydrogenase shows promise in normalizing glucocorticoid metabolism and restoring responsiveness to antiandrogen therapy. This perspective reviews what we have learned about this resistance mechanism, examines potential implications, and considers how this knowledge might be harnessed for therapeutic benefit.Keywords
Funding Information
- National Cancer Institute (R01CA172382, R01CA190289, R01CA236780)
- Prostate Cancer Foundation
This publication has 8 references indexed in Scilit:
- Hexose-6-phosphate dehydrogenase blockade reverses prostate cancer drug resistance in xenograft models by glucocorticoid inactivationScience Translational Medicine, 2021
- Back where it belongs: 11β-hydroxyandrostenedione compels the re-assessment of C11-oxy androgens in steroidogenesisMolecular and Cellular Endocrinology, 2021
- Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposureAnnals of Oncology, 2020
- Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus PrednisoneEuropean Urology, 2019
- Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancereLife, 2017
- Glucocorticoid Receptor Activity Contributes to Resistance to Androgen-Targeted Therapy in Prostate CancerDiscover Oncology, 2014
- Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor BlockadeCell, 2013
- Hexose-6-phosphate Dehydrogenase Knock-out Mice Lack 11β-Hydroxysteroid Dehydrogenase Type 1-mediated Glucocorticoid GenerationJournal of Biological Chemistry, 2006